A trial of SYS6026 vaccine for HPV16/18-related high-grade cervical lesions
Part of Women’s health & pregnancy clinical trials.
This trial tests a new vaccine (SYS6026) for women with high-grade cervical lesions caused by HPV type 16 or 18. It aims to see if the vaccine can help the body clear these precancerous cells, potentially avoiding surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a cervical infection with HPV type 16 and/or 18.
- You must have a high-grade cervical lesion (CIN 2 or CIN 3) confirmed by biopsy.
- You must be willing to have a biopsy during screening and again at 36 weeks.
- You must have normal organ function (kidney, liver, blood counts, etc.).
- If you could become pregnant, you must use reliable birth control for at least a year after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This trial tests a new combination therapy for advanced solid tumors that have HPV type 16 or 18. It aims to see if the treatment is safe and works against the cancer.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial is testing a new vaccine designed to help your immune system fight cervical cancer caused by HPV types 16 or 18. It is for women who are receiving standard treatment like surgery, chemotherapy, or radiation.
This study tests a new injection (RG002) for women with a cervical precancer called CIN 2 or CIN 3 that is caused by HPV types 16 or 18. The goal is to see if the treatment can help the body clear the precancer without needing surgery.
Hear when a new High-grade Cervical Intraepithelial Lesions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.